Dynavax Technologies Corporation (DVAX)

Lifshitz & Miller announces investigation on behalf of DVAX investors concerning whether DVAX adequately disclosed DVAX's phase 3 trial for lead vaccine product HEPLISAV-B.

If you are a DVAX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.